2.4 Genotyping
The CYP3A5*3 (rs776746) genotype was determined using the Sanger
dideoxy DNA sequencing method. Genomic DNA was extracted from
EDTA-anticoagulated peripheral blood samples using a commercially
available DNA purification kit (EasyPure Blood Genomic DNA Kit,
Transgene Biotech, Beijing, China). Subsequently, genomic DNA samples
were amplified via polymerase chain reaction (PCR) and sequenced
utilizing the ABI 3730XL DNA Sequencer (ABI Co; Majorbio Biotechnology
Co.,Ltd., Beijing, China). The forward primer was
5’-CAGCATTTAGTCCTTGTGAG-3’, and the reverse primer was 5’-
ACGACACACAGCAACCTTAG-3’. Data analysis was performed using Chromas
software (Technelysium, South Brisbane, Australia). Patients carrying
the *1 allele (CYP3A5*1/*1 or *1/*3 ) were
categorized as CYP3A5 expressers, while those with theCYP3A5 *3/*3 genotype were classified as CYP3A5Non-expressers.